Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Sarcoma 3Carcinoma, Renal Cell 3Leiomyosarcoma 2Solid Neoplasm 1Sarcoma, Synovial 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Refractory or Recurrent Solid Tumor 1Recurrence 1Perivascular Epithelioid Cell Neoplasms 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Nerve Sheath Neoplasms 1Liposarcoma 1Kidney Neoplasms 1Histiocytoma, Malignant Fibrous 1Histiocytoma, Angiomatoid Fibrous 1Granuloma, Plasma Cell 1Glioblastoma 1Fibrosarcoma 1Dermatofibrosarcoma 1Chondrosarcoma, Mesenchymal 1Chondrosarcoma, Extraskeletal Myxoid 1Carcinosarcoma 1

Interventions

pazopanib 1Geriatric Assessment 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Solid Neoplasm × pazopanib × Clear all
NCT01552356 2026-04-13

Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
54 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡